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Abstract
Background: Diabetes costs represent a large burden to both patients and the health care system. However, few studies
that examine the economic consequences of diabetes have distinguished between the two major forms, type 1 and type 2
diabetes, despite differences in underlying pathologies. Combining the two diseases implies that there is no difference
between the costs of type 1 and type 2 diabetes to a patient. In this study, we examine the costs of type 1 diabetes, which is
often overlooked due to the larger population of type 2 patients, and compare them to the estimated costs of diabetes
reported in the literature.
Methodology/Principal Findings: Using a nationally representative dataset, we estimate yearly and lifetime medical and
indirect costs of type 1 diabetes by implementing a matching method to compare a patient with type 1 diabetes to a similar
individual without the disease. We find that each year type 1 diabetes costs this country $14.4 billion (11.5–17.3) in medical
costs and lost income. In terms of lost income, type 1 patients incur a disproportionate share of type 1 and type 2 costs.
Further, if the disease were eliminated by therapeutic intervention, an estimated $10.6 billion (7.2–14.0) incurred by a new
cohort and $422.9 billion (327.2–519.4) incurred by the existing number of type 1 diabetic patients over their lifetime would
be avoided.
Conclusions/Significance: We find that the costs attributed to type 1 diabetes are disproportionately higher than the
number of type 1 patients compared with type 2 patients, suggesting that combining the two diseases when estimating
costs is not appropriate. This study and another recent contribution provides a necessary first step in estimating the
substantial costs of type 1 diabetes on the U.S.
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Introduction
Type 1 diabetes (T1D) is an autoimmune disease, often
diagnosed early in life, characterized by the destruction of the
insulin-secreting b cells in the pancreas. As a consequence,
patients become insulin-dependent and must follow a rigid, daily
regimen of exogenous insulin replacement. In contrast, type 2
diabetes (T2D) is typically a disease of adulthood (although more
cases are now being seen earlier in life), where a relative insulin
deficiency arises due to insulin resistance and abnormal
pancreatic b cell function [1]. The American Diabetes Associa-
tion (ADA) estimates that there are 17.9 million individuals
diagnosed with diabetes in the U.S. [2], with 5 to 10 percent
representing those with T1D [3]. Epidemiologic studies suggest
that the incidence rate of T1D has been growing worldwide,
especially amongst young children [4].
With the increasing focus on the T2D epidemic, the impact of
T1D in this country is often overlooked, particularly from an
economic perspective. Many cost-of-illness (COI) studies have
been performed on diabetes, but most combine the costs for T1D
and T2D over just one year. The Agency for Health Research
Quality (AHRQ), using the Medical Expenditures Panel Survey
(MEPS), a nationally representative data set [5], reports that $34
billion in health expenditures were related to diabetes in 2005 [6].
A frequently quoted study by the ADA improves upon this
number by using the attributable risk methodology to calculate the
portion of expenditures on related comorbidities that is due to
diabetes [7]. The researchers also include other non-medical costs
(i.e. lost work days, bed days, and increased mortality), which are
important factors in the cost of diabetes. The study finds that
diabetes is responsible for $92 billion in medical expenditures and
$40 billion in indirect costs in 2002. An ADA update finds that in
2007 the total cost of diabetes had increased to $174 billion ($155
billion in 2002 dollars), the increase in costs due to increased
populations of diabetics [2]. Another recent study projects that the
costs of the diabetes epidemic will have risen to $336 billion (2007
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million [8].
These studies do not break down diabetes costs by type in their
estimates. Rather, they attempt to apply the proportion of patients
with type 1 to obtain the fraction of costs attributed to type 1, an
assumption that does not account for the distinct nature and
differing disease progressions of the two forms of the disease.
Furthermore, there is wide variation in results among the cost
studies. For example, a study by the Milken Institute calculates
combined T1D and T2D indirect costs to be over $105 billion in
2003 [9]. The discrepancy is due to the inclusion of differing cost
components and varying underlying methodologies. Studies that
do specifically examine the T1D population concentrate on
children, are not nationally representative, are not U.S. based, or
only look at medical expenditures [10–12]. One recent exception
by Dall et al. [13], using medical claims data to identify T1D
patients, compares the annual costs of T1D with T2D in the U.S.
and finds the costs of T1D to be disproportional to the number of
T1D patients compared with the number of T2D patients.
Patients with T1D typically suffer from the disease for a longer
period of time. Regular maintenance of T1D requires daily insulin
shots and constant monitoring, representing a significant lifelong
cost and time requirement. For T1D, these long-term effects are
likely to spill over to other aspects of their lives with resulting
economic impacts particularly in indirect costs. Milton et al. [12]
compile and review studies in the literature addressing the social
consequences of T1D. The evidence is mixed. They find that
children with T1D are more likely to miss school and that the
employment outcomes are worse, but school performance and
educational attainment remain unaffected. Providing lifetime cost
estimates, as well as annual costs, would allow comparison among
diseases that take into account the full economic impact of chronic
diseases and facilitate discussions of benefits of possible cures.
To address these deficiencies and provide a comprehensive first
step in identifying the annual and lifetime costs of T1D, this study
was designed to estimate the direct medical expenditures and
indirect costs associated with T1D in the U.S. Together with more
traditional biomedical research into the causes and treatments of
T1D, this study allows for a comprehensive understanding of the
costs and benefits associated with the disease. Doctors, patients,
researchers, policy makers, and drug developers can use these
results to more fully understand the impact of T1D on individuals
and society.
In this paper, we present the results of this analysis that show, as
might be expected given the different disease pathologies that
underlie the forms of diabetes, that the cost breakdown in T1D is
different than T2D, with indirect costs being disproportionately
larger for T1D. Furthermore, we show that over a lifetime, the
economic costs of T1D are in excess of $10 billion for a new yearly
cohort of approximately 30,000 patients.
Materials and Methods
Using nationally representative data sets, we identify T1D
patients and examine direct medical expenditures and indirect
costs associated with the disease by matching a T1D patient to a
counterpart without diabetes. Since finding an exact match
becomes increasingly difficult as more covariates are used, we
implement the propensity score matching (PSM) technique first
introduced by Rosenbaum and Rubin [14] and frequently used in
the program evaluation literature.
Although matching is not new to cost studies, few match on
more than simply age, gender, and race. However, to obtain an
unbiased and accurate measure of costs attributed to T1D, the
matched control individuals must be as similar to the population
with T1D as possible so that the only difference between the two
can be attributed to T1D. This is not likely to be the case if
matching is based on only a few broad demographic variables.
The matching method compares with other cost estimation
methods such as those used by the ADA, which require detailed
and accurate knowledge of the relationship between diabetes and
its comorbidities [2,7]. Matching methods do not require this
knowledge, but there is a trade-off; matching does not work well
when important unobservable differences between those with and
without the disease exist, as is true for T2D [15]. For example,
preferences, life style choices, and genetics are highly correlated
with the probability of having T2D. Although MEPS contains
some information on exercise habits, diet and the health of family
members (except for those living in the same household as
relatives) are unknown. However, T1D is a good candidate for
matching because unlike T2D, the presence of unobservable
factors that affects the probability of having the disease is minimal.
In fact, 80 percent of T1D patients do not have a family member
with the disease, and behavioral and environmental causes are not
definitively known [16,17].
Matching
Ideally, one would like to observe the diabetic counterfactual—
the life of a patient with diabetes had he not had diabetes—and
attribute all differences to diabetes. Of course, the counterfactual
does not exist in real life, and therefore the notion of a nondiabetic
diabetic-type is pertinent. This is equivalent to the nonsmoker
smoker-type, which is used in the smoking literature to determine
the cost of smoking [18–20]. The nondiabetic diabetic-type does
not have T1D, but is the same as a patient with T1D in regards to
any differences that distinguish a patient with diabetes from an
individual who does not have the disease, including morbidity,
mortality, and medical care use. Compared with a fully
nondiabetic individual, the nondiabetic diabetic-type individual
may use more medical care and experiences a higher mortality
rate. On the other hand, compared with an actual patient with
T1D, the nondiabetic diabetic-type uses less medical care and has
a lower mortality rate, with the difference being attributable to
T1D. T1D is not definitively linked with particular behaviors or
environmental factors, though research has suggested some
possible associations. We include relevant covariates to determine
the nondiabetic diabetic-type sample.
Matching each diabetic with a nondiabetic diabetic-type and
attributing any differences to T1D requires several assumptions
[14]. The first is the Conditional Independence Assumption (CIA),
which is stated as follows:
Let y0 be the outcome (such as medical expenditures) for
a person without T1D.
Let y1 be the outcome for a patient with T1D.
Let D be an indicator for having T1D.
Then,
y1,y0 ðÞ \DDX ð1Þ
where X are the covariates used for matching a patient with T1D
to a nondiabetic diabetic-type and H indicates independence. The
outcomes y0 and y1 are independent of whether or not the
individual has T1D, after conditioning on all the covariates in X.
In other words, after matching on X, having T1D is the only
difference between a T1D patient and his matched counterpart
that affects the outcome. The assumption is strong and requires
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that affect both the probability of T1D and the outcome of
interest.
Including more observable characteristics for matching im-
proves the results of the matching estimator, but makes it
increasingly difficult to find an exact match for each individual
with diabetes. Matching based on propensity scores addresses this
problem by providing a natural weighting scheme for potential
matches. The propensity score is the probability of receiving
‘‘treatment’’ conditional on the observable characteristics [14]. In
this case ‘‘treatment’’ is the condition of T1D. The probability of
having T1D is regressed on a list of covariates through a logit or
probit regression. Each individual receives a score based on his
predicted probability of having T1D. The individual is then
matched pairwise (or some other way) to a nondiabetic by this
predicted probability, or score. The propensity score can be
written as
PS~P(DDX) ð2Þ
The CIA then becomes (y1,y0)\DDPS. A second assumption of
common support is necessary.
It is written as 0vPSv1, and asserts that there is no perfect
predictability of D given X. Individuals with the same X have
positive probability of having T1D.
T1D patients are matched using the propensity score to
individuals in a control group of those without diabetes. The
difference in outcomes between the patients and their matched
counterparts is called the average treatment on the treated. It is the
portion that can be attributed to T1D. It is written as
ATT~
1
Nd
X
i[D
yi{
X
j[Cj
w(i,j)yj
2
4
3
5 ð3Þ
where
yi is the outcome for an individual with T1D
yj is the outcome for a nondiabetic diabetic-type
Nd is the number of people with T1D
Cj is the set of matched control individuals for the T1D
patients
w(i,j) is the weighting function that depends on the PSM
method.
The simplest weighting method is a 1 to 1 nearest neighbor
matching. The difference between the two groups is then the
average difference between the outcome of a T1D patient and his
matched counterpart. The average treatment cost difference
between a patient with T1D and a person without diabetes is:
ATT~
1
Nd
X
i[D
yi{yj
  
ð4Þ
Matching can be done with or without replacement. Replacement
decreases the bias by ensuring a better fit, but increases variance
since fewer observations are being used. The main analysis in this
study uses a logit specification to estimate the T1D propensity
score and one-to-one matching with replacement. There are other
weighting methods. In testing the sensitivity of the matching
method, we use kernel density matching, which uses the all
nondiabetics for comparison, but weights their importance by the
propensity score. We do not find the results to differ from our
main analysis. Standard errors are calculated by bootstrapping
with 500 iterations. Using the calculated standard errors, we
report 95 percent confidence intervals for all results.
Matching assessment
A difficult part of the matching process is the determination of
appropriate covariates for matching. There is no hard and fast rule
for choosing covariates, but there should be a theoretical reason
for why the covariate affects both the probability of having T1D
and the outcome of interest [21]. Further, it is important that the
covariates included are not affected by T1D. For example, say we
wished to include family size as an explanatory variable for the
likelihood of T1D. Assuming that the parents of T1D patients are
less likely to have many children (due to the extra time and
resources committed to caring for T1D patients), then the impact
of family size on the likelihood of T1D would be confounded since,
in this scenario, children with T1D would tend to have fewer
siblings. The covariates we include come from the medical
literature and vary by the strength of evidence [22,23].
After matching on propensity scores, the match quality is
evaluated by comparing the means of the T1D group and the
matched control group. Since matching is made on propensity
score, which is weighted naturally by the importance of each
variable, the means are not expected to all be exactly the same, but
should be close. In general, sample differences in the unmatched
case exceed those in the matched case. To quantify the differences
between the unmatched and matched samples, we define the
following [24,25]:
Bias~
100(xD{xC)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2
Dzs2
C
2
s
                   
                   
ð5Þ
where xD and s2
D are the sample mean and variance for the T1D
sample, and xC and s2
C represent the same for the control sample.
Identifying T1D patients
One likely cause of the small amount of T1D cost studies is the
difficulty in distinguishing patients with T1D from those with T2D
in secondary data. Most population surveys simply ask whether a
person has ever been told by a physician that he has diabetes, and
data with detailed medical tests are not nationally representative.
One exception is the National Health and Nutrition Examination
Survey (NHANES) [26], which administers a c-peptide test for
T1D. However, due to the small number of patients with diabetes
sampled by NHANES, we use ‘‘clinically-derived definitions’’ to
identify individuals with T1D using age of onset, body mass index
(BMI), and usage of insulin therapy. The Diabetes Care Survey
(DCS), part of MEPS, collects information on individuals who self
report having diabetes. However, the DCS does not obtain the age
when the individual was first diagnosed with diabetes, but this
information can be obtained from the National Health Interview
Survey (NHIS) [27]. The MEPS can be linked to the NHIS since
MEPS participants consist of a subsample of NHIS participants
drawn a year later, allowing variables to be shared between the
two data sets. The DCS is available starting from 1999. We pool
data from 1999 to 2005, the most recent year with available data,
to generate our sample.
Other studies also categorize diabetes based on their patterns of
drug use during the study period [10,28]. For example, Koopman
et al. [29] use an age of onset and the exclusive use of insulin for
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of these criteria using the NHANES, Prior et al. [30] finds that
clinically-derived definitions generally work well to distinguish
T1D and T2D. However, categorizing T1D using these
qualifications can lead to both over- or under- estimates of the
number of T1D patients. A strong indicator of T2D in a child is
being overweight or obese [31,32]. Therefore, we refine the
definition of individuals with T1D by eliminating children under
the age of 18 who report having diabetes and who are also
considered obese. Obesity in children is defined as having a BMI
equal to or greater than the 95th percentile by age [33]. The
number of T1D patients is underestimated by the number of
individuals diagnosed with T1D over the age cutoff we use. This
includes those who are misdiagnosed with T2D because of their
age. For example, Latent Autoimmune Diabetes of the Adult
(LADA) occurs in adults over the age of 30 and is commonly
misdiagnosed as T2D in the early stages of the disease. An
estimated 10 percent of adults diagnosed with T2D are
misdiagnosed and truly have T1D [34,35]. Since the typical
LADA patient is non-obese, we limit the sample to patients whose
BMI is 30 or less if they are diagnosed over age 30 [36,37]. Cusick
et al. [38] also employ a weight qualification to obtain their T1D
sample. An age 30 cutoff is perhaps the most common in the
literature, though studies do use later cutoffs [39] as we do in this
study. We limit the sample to include only patients that report
currently using insulin. The data set only provides current BMI
and therefore a T2D patient diagnosed over the age of 30 who was
obese at the time of diagnosis, but who lost weight by the time of
the survey, would be categorized as having T1D. In order to avoid
underestimating the LADA population, the main analysis uses 45
as the age of diagnosis cut off, which represents 1.1 million T1D
patients.
Estimating yearly costs
Yearly costs are those incurred in an average year between 1999
and 2005. The medical expenditures considered in this study are
total expenditures and therefore include self-payments and any
third-party payments. In particular, they consist of hospital
inpatient, ambulatory visits (consisting of hospital outpatient and
physician office-based), emergency room and prescription drug/
medical supplies, home health provider, and vision and dental
utilization expenditures.
Indirect, or productivity costs, are not as straightforward to
measure, and income is frequently used to measure productivity
losses due to illness [7]. MEPS divides income evenly between the
adults in the household, unless the share of total income by each
adult is obtained. To be consistent, we split income evenly between
spouses for all applicable cases in our sample. Therefore, even if
one member of a family does not generate a market income, he
may be coded as having half his spouse’s income. A nonworking
spouse would therefore be assigned an income, though it possibly
is not reflective of his or her productivity. Additionally, Brouwer
et al. [40] note that income may not completely reflect
productivity due to social benefits and presenteeism (reduced
performance when at work). To address these issues, we consider
additional productivity measures such as total household income,
lost work days, bed days and missed school days. To prevent
double-counting, these measures should not be added to income
loss; we list them separately.
To estimate productivity losses attributed to early mortality
caused by T1D, we compute the present value of future
productivity (PVFP) [2]. We estimate the PVFP for those who
died by summing expected earnings every year by age and
discounting by a three percent discount rate [41]. To estimate the
expected earnings profile for each individual, we use the income
distribution by age of the current patients in the sample,
accounting for the probability of dying every year. To determine
the expected number of deaths of T1D patients, we use the
mortality rates from the literature and the current number of
patients [42,43]. We assess the cost attributed to T1D by
performing the same PVFP calculation on the matched control
sample using national mortality rates and attributing the difference
to the disease [44].
Propensity score matching ensures that we account for all
observed variables in determining the control sample and the
subsequent effects on outcomes. However, the results will be
biased if an unknown, unobserved factor affects whether an
individual has T1D and also the outcomes we observe. A
Rosenbaum bounds test can be performed to verify that our
findings are not driven by a potential omitted variable [25,45].
The existence of this unobserved variable and its omission from
the model would bias the estimated effects of T1D. We find that
our results are insensitive to a bias unless an unobserved factor
more than doubled the odds of having T1D, allowing us to be
reasonably certain that our methods accurately estimate the effect
of T1D.
Estimating lifetime costs
Since T1D patients are typically diagnosed at an early age
compared to typical T2D patients and T1D patients therefore
suffer from the disease for a longer portion of their life, lifetime
costs are better for capturing the full burden of the disease and
providing a fairer, more accurate, comparison between diseases.
We use two approaches for measuring lifetime costs. First, we
estimate the lifetime costs of a cohort of newly diagnosed patients
by generating a longitudinal profile of costs from the cross-sections
of patients in our sample stratified by current age and age of
diagnosis. Second, using this longitudinal profile we estimate the
amount incurred by the current population over the rest of its
lifetime. The first approach seeks to measure the amount saved by
a future cohort of newly diagnosed patients if onset of T1D could
be prevented. The second method finds the savings by the current
patient population if a cure (i.e., means to prevent or reverse the
disease) were discovered today. These calculations admittedly
neglect improvements in health care technology over time, but
similar methods have been used to estimate the lifetime costs
associated with smoking and obesity [20,46].
To obtain expected expenditures, we divide the sample into
seven age groups, starting with age group 3 to 18 (age 3 is the age
of the youngest T1D patient in the sample). Sample size limitations
prevented us from breaking down the 18 and under age group into
smaller groups. We multiply total expenditures at each age by the
probability of surviving to that age using published survival
probabilities [44]. To obtain mortality rates of individuals with
and without T1D, we use estimates from the literature on the
relative mortality rates of diabetes patients vs. individuals without
diabetes [42,43]. Unfortunately, the relative death rates estimates
from Gu et al. [42] do not distinguish between T1D and T2D.
There is evidence that mortality rates are higher amongst patients
with T2D, though early mortality rates are higher for T1D
patients [47]. However, Cusick et al. [38] finds lower 5-year
mortality rates amongst patients with T1D than patients with
T2D, and Juutilainen et al. [48] find the risk of mortality from
cardiovascular disease to be similar between T1D and T2D
patients. As the results are inconclusive, we use figures from Gu et
al. [42] since the data source is nationally representative data.
However, although Gu et al. [42] note that mortality rates are
higher for those patients with a longer history with diabetes, they
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diabetes, which would be an important area for future studies to
examine. Furthermore, Gu et al. [42] do not provide mortality
rate estimates for those under age 25. For mortality estimates of
those under 25, we use figures from Dahlquist and Kallen [43] on
the relative mortality children with T1D diagnosed between ages 0
to 14 compared with children without diabetes.
We calculate the present value of expected costs by discounting
the stream of expenditures at a rate of three percent, as
recommended by the World Health Organization [41].
Expected lifetime expenditures are described by
X 70z
t~3{18
EtPt(1zi)
{(t{10) ð6Þ
where
Et=expenditures during age interval if the individual
survives through t
Pt=probability of surviving through age interval
t=10, 25, 35, 45, 55, 65, 70+
i=discount rate.
To estimate the size of the yearly cohort of new T1D patients,
we use published T1D incidence rates and total population counts
from the 2000 Census [4,49]. We calculate the effect of preventing
the disease by multiplying the number of new patients at each age
by the present value of expected lifetime costs. Similarly, we
compute the savings from a cure for T1D by multiplying the
current number of T1D patients by the present value of expected
lifetime costs. The difference between the present value of
expected lifetime expenditures of patients with T1D and that of
their matched counterparts is attributable to T1D.
Results
T1D population
Table 1 reports the number of unweighted and weighted
observations classified as T1D using various cutoff ages for
diagnosis. Note that this sample is only representative of the
civilian noninstitutionalized population, leaving out patients with
T1D in nursing homes or the military since MEPS does not collect
information on these populations.
Table 2 reports the size of MEPS sample. By combining data
from 1999 (when the DCS began) to 2005 (the most recent year
with available NHIS data), the total sample consists of 194,115
person-years. Using the MEPS sample weights, this represents 262
million non-institutionalized, civilians in an average year. Of the
11,071 that report having diabetes that have available data, 817
were diagnosed at or before age 45, are currently on insulin, and
are not obese if they were diagnosed over the age of 30. The 817
person-years represent 1.1 million patients with T1D nationally in
an average year between 1999 and 2005. The control group
consists of those person-years where no diabetes (type 1 or type 2)
is reported. The unweighted potential control group consists of
183,044 person-years. Table 3 shows the sample sizes by age of
onset for each age group.
Table 4 summarizes the results of the propensity matching
assessment. The first three columns of Table 4 report the covariate
means of key variables for the T1D group, the entire control
group, and the matched control group. The average age of a T1D
patient in the sample is 48 years and over half of the sample is
female. Twenty percent of the patients under 18 with T1D also
report having eczema. The bias is computed for the matched and
unmatched control cases (fourth and fifth columns of Table 4).
The last column of Table 4 reports the percentage reduction in
bias between the matched and unmatched control cases. The bias
reduction in propensity score is nearly 100 percent. In general, the
bias for each covariate is greatly reduced by at least 80 percent.
However, the matched cases do not match well on years spend in
the US and birth weight, which applies for those under 18.
We examine the joint significance of the regressors in the logit
estimation before and after matching. They are jointly significant
before matching with an F-statistic of 19.3. When we rerun the
estimation using just the T1D patients and the matched controls,
we cannot reject the hypothesis that the covariates have no
explanatory power, which indicates that the covariates are able to
predict whether the individual has T1D. In other words,
conditional on the propensity score, T1D is ‘‘randomly’’ assigned
to either group.
To confirm the validity of T1D sample of 1.1 million patients in
the MEPS, we apply the same T1D clinically-derived definitions
that were described above to the NHANES data. We find a
sample representing 1.4 million individuals nation-wide who have
T1D, slightly larger than the MEPS sample. This figure is based
on NHANES data for an average year between 1999 and 2004.
The actual number of T1D patients is 140, weighted to represent
1.4 million persons.
NHANES collects information on fasting plasma glucose levels
and c-peptide levels of a subset of their sample. A fasting plasma
glucose level of 126 mg/dl or over indicates diabetes [32].
Table 1. T1D sample size by age of diagnosis.
a
Age of diagnosis N
Sample weighted total
for average year (1999–2005)
30 or younger 563 756,377
35 or younger 632 855,697
40 or younger 721 966,238
45 or younger 817 1,089,755
aThe patient is categorized with T1D if he reports being told by a physician that
he has diabetes, is currently using insulin, and is diagnosed at or before age 45.
We include patients under age 18 only if they are not considered obese.
Patients diagnosed later than age 30 are only included if their BMI is 30 or
lower.
doi:10.1371/journal.pone.0011501.t001
Table 2. Sample sizes, weighted and nonweighted.
Description N
Sample weighted
total for average
year (1999–2005)
Person-years with MEPS & NHIS data 194,115 262 million
Answered ‘Yes’ to ever been
diagnosed with diabetes
11,071 15.1 million
Categorized as T1D patient
a 817 1.1 million
Potential control group (no diabetes
diagnosis)
183,044 246 million
aThe patient is categorized with T1D if he reports being told by a physician that
he has diabetes, is currently using insulin, and is diagnosed at or before age 45.
We include patients under age 18 only if they are not considered obese.
Patients diagnosed later than age 30 are only included if their BMI is 30 or
lower.
doi:10.1371/journal.pone.0011501.t002
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0.5 nmol/L or lower can be used to identify T1D patients [50].
Using these qualifications, the NHANES categorizes approxi-
mately 600,000 individuals with T1D nation-wide. However, only
400,000 of the patients categorized as T1D using our clinically-
derived definitions had available plasma glucose and c-peptide test
information. About 40 percent of the individuals defined as a T1D
patient using our clinically-derived definitions who have available
test data report a c-peptide test of less than 0.5 nmol/L and a
plasma glucose of over 126 mg/dl, but fewer than 5 percent of
T2D patients defined using our clinically-derived definitions
display these test results (results available upon request). This
information confirms that we are not likely leaving out many true
T1D patients from our sample, but it is possible that we are
including T2D patients in the sample.
Medical costs
Table 5 reports medical expenditures attributed to T1D for
hospital, ambulatory visits (office-based and outpatient), prescrip-
tion drug (including medical supplies) and emergency room visits
for an average year between 1999 and 2005 in 2005 dollars. The
first column shows the mean yearly expenditure for patients with
T1D by medical care type. All medical events in MEPS are self-
reported. Therefore, it is possible that a hospital visit that started
out as an emergency room visit was reported as simply a hospital
visit and coded that way. MEPS does provide a variable that
indicates whether a hospital visit began with an ER visit. However,
we are unable to allocate those costs between the ER and hospital
inpatient share of the visit. The second column lists medical
expenditures by type of medical care for the matched control
group of individuals without diabetes. The mean total yearly
medical expenditures for the T1D group are nearly $10,000, and
the expenditure for their matched counterparts is $3,580. The
difference between the T1D group and the matched control group
is the mean yearly value attributed to T1D and is $6,288 (4,426 to
8,150) in total medical expenditures. Expenditures on hospital
visits, prescription drug and ambulatory visits are significantly
different between the T1D and control group at the 1 percent
significance level. Emergency room costs attributed to T1D are
significantly different from zero at the 10 percent significance level.
While some patients with T1D may not experience any serious
complications,complicationsthatdoarisecanbequitesevereand are
likely to lead to more intensive medical care. We attempt to examine
the medical use of patients with T1D with complications by using
hospital nights as an indicator for complications. Of the 817 person-
yearsin the T1D sample, 605report zero hospital nights. Limiting the
results to the 212 who do report at least one hospital night and
comparingthemwiththeirmatchedcounterpartsyieldsresultsshown
in Table 6. Average medical expenditures are substantially higher for
the limited sample that report at leastone hospital night. Patients with
T1D with at least one hospital night spend $25,858 in total medical
expenditures. The matched control spend $2,720. Average yearly
total medical expenditure attributed to T1D then jumps to $23,137
(17,288 to 28,986) per year.
Indirect costs
Indirect costs for patients with T1D and their matched
counterparts during an average year are listed in Table 7. Work
days and bed days are significantly different for the two groups.
Patients with T1D miss on average 5.5 (3.2 to 8.4) more days than
individuals without diabetes per year and experience 7.6 more bed
days. Bed days may include lost work days, so the two should not be
added. T1D patients under 18 miss 3.3 (2.1 to 4.0) more school days.
Individual income (individual income is compared only for thoseover
18 years of age) for patients with T1D is$7 , 1 6 4( 9 , 2 6 8t o6 , 0 0 8 )l o w e r
than incomeof individuals without diabetes, and householdincome is
$9,480 (5,701 to 11,034) lower for T1D patients.
Lifetime costs attributed to T1D
Table 8 reports average yearly medical expenditures attributed
to T1D by age group. On average, an individual aged 3 through
18 incurs an additional $1,981 (2918 to 4,880) in medical
expenditures per year due to T1D. However, this figure is not
significant. T1D attributable expenditures rise for the most part to
a peak in the 65 to 74 age group and decrease slightly after that. At
older ages, nondiabetes related medical conditions may be the
main driver of medical expenditures, especially if those who
survive to this tend to be healthier.
Table 9 reports the expected lifetime medical cost and income
loss attributable to T1D by age of onset for a new cohort of T1D
patients. We estimate the size of the cohort of new T1D patients to
be 28,430 in an average year between 1999 and 2005, which is
consistent with various other findings [48]. The largest number of
Table 3. Number of Type 1 Diabetes Patients by Current Age and Age of First Diagnosis (Sample Weighted Below).
Current Age
Age of Diagnosis 3–18 19–29 30–39 40–49 50–64 65–74 75+ Total
0–18 65 42 41 45 47 12 13 265
71,036 57,253 60,994 64,154 76,812 13,813 18,643 362,706
19–29 - 50 63 56 65 14 9 257
66,528 82,404 71,685 91,001 8,609 11,309 331,537
30–39 - - 23 41 65 24 5 158
38,747 60,093 86,567 29,740 7,075 222,222
40–45 - - - 14 76 20 27 137
17,491 92,980 29,222 33,597 173,290
Total 817
Sample Weighted 1,089,755
Note: The patient is categorized with T1D if he reports being told by a physician that he has diabetes, is currently using insulin, and is diagnosed at or before age 45. We
include patients under age 18 only if they are not considered obese. Patients diagnosed later than age 30 are only included if their BMI is 30 or lower.
doi:10.1371/journal.pone.0011501.t003
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consequently faces the greatest share of expected lifetime
expenditures due to T1D. The present value of expected medical
and indirect costs for the whole cohort of new T1D individuals is
$3.3 billion (2.1 billion to 4.5 billion) and $7.3 billion (4.5 billion to
10.1 billion), respectively.
Table 10 shows the expected lifetime medical and indirect costs
by age for the current T1D patients in the sample. The present
value of expected lifetime costs attributed to the disease for the 1.1
million T1D patients estimated in an average year between 1999
and 2005 was $133.7 billion (97.0 billion to 170.4 billion) in
medical expenditures and $289.2 billion (211.7 billion to 366.7
billion) in lost income.
Discussion
The CDC finding that T1D accounts for 5 to 10 percent of all
diabetes cases remains a popular benchmark [3]. Due to an aging
Table 4. Propensity score matching assessment – bias reduction from using a matched vs. unmatched sample.
Variable T1D
a (N=817)
Unmatched control
a
(N=183,044)
Matched control
a
(N=817) Bias (Unmatched) Bias (Matched)
Percent bias
reduction
Propensity Score 0.20 0.09 0.20 100.1 0.0 100.0
Age (years) 48.44 34.80 47.84 70.0 3.5 95.0
Female 0.56 0.52 0.53 6.5 5.8 10.3
MSA 0.76 0.79 0.75 8.4 1.1 87.0
Non White 22.01 19.94 22.27 5.1 0.6 87.8
Northeast 0.14 0.16 0.15 3.5 0.7 80.1
Midwest 0.20 0.21 0.20 1.2 0.0 99.5
South 0.41 0.37 0.42 8.1 0.9 88.7
West 0.23 0.27 0.24 7.5 0.7 90.9
Year 1999 0.07 0.13 0.07 21.0 0.3 98.7
Year 2000 0.09 0.14 0.08 14.3 2.3 83.7
Year 2001 0.21 0.18 0.20 9.8 3.1 68.4
Year 2002 0.24 0.21 0.24 8.6 0.7 91.8
Year 2003 0.20 0.18 0.22 5.6 5.8 22.3
Year 2004 0.19 0.18 0.18 2.8 1.7 38.8
Birth Weight (ozs)
b 112.90 117.67 122.40 17.1 28.2 264.8
Height (inches) 66.20 66.84 66.90 15.9 17.6 210.5
U.S. Citizen 0.95 0.90 0.90 17.8 19.7 210.6
In U.S.,15 Years 0.18 0.37 0.03 41.6 52.5 226.3
Eczema
b 0.20 0.06 0.20 40.7 0.0 100.0
Arthritis 0.34 0.12 0.28 51.7 11.0 78.8
Cancer 0.04 0.02 0.04 8.3 0.7 91.5
Mom Finished HS
b 0.56 0.39 0.56 35.1 0.0 100.0
Dad Finished HS
b 0.44 0.27 0.44 35.5 0.0 100.0
aAll values are percents unless otherwise noted.
bData available for those under 18 years of age only.
doi:10.1371/journal.pone.0011501.t004
Table 5. Mean yearly and total yearly medical expenditure for patients with T1D and matched controls (2005 dollars).
Outcome T1D (1) Matched control (2) Attributed to T1D
a (1)–(2)
Hospital Inpatient 3,506 956 2,550 (1,184–3,916)
***
Ambulatory Visits 2,485 1,295 1,190 (470–1,909)
***
Prescription Drug 3,089 823 2,266 (1,956–2,576)
***
Emergency Room
b 222 125 97 (21–195)
*
Total Medical Expenditure (per capita)
c 9,868 3,580 6,288 (4,426–8,150)
***
aNinety-five percent confidence intervals in parentheses. ***, **, * indicate the 1 percent, 5 percent and 10 percent significance levels, respectively.
bER visits are likely under-reported. It is possible that a hospital visit that started out as an emergency room visit was reported as simply a hospital visit, and coded that
way. Although MEPS does provide a variable that indicates if a hospital visit began with an ER visit, we would not know how to allocate the costs between ERa n d
hospital, so we do not use this variable.
cOutcomes do not add up to total because total medical expenditure includes some other factors (home health care, vision, etc.) that are each small.
doi:10.1371/journal.pone.0011501.t005
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ments in detection, the number of T2D patients has been rapidly
growing [2,7]. Although some studies have shown that the number
of patients with T1D is increasing as well [4], there is no obvious
reason to believe that rate of increase between the two major types
of diabetes should be related. With the rapid growth in the
prevalence of T2D, using the commonly cited 5 to 10 percent
benchmark can lead to widely varying figures on the number of
T1D cases. For example, The Juvenile Diabetes Research
Foundation International (JDRF) lists as high as 3 million patients
with T1D as a figure on its website [51]. We identify 1.1 million
T1D patients, which falls at the lower end of the 5 to 10
percentage range of the total number of individuals with diabetes
reported by the ADA and CDC. According to the CDC, 5 to 10
percent of the number of total individuals with diabetes per year in
1999 through 2005, was 790,000 to 1.6 million T1D patients [52].
Dall et al. [13], using different data and ICD-9-CM diagnosis
codes to identify T1D patients, also find a T1D patient population
of 1 million, similar to our estimate of 1.1 million T1D patients.
Medical Costs
We find total yearly medical expenditure attributable to T1D to
be $6.9 billion (5.9 billion to 7.9 billion) over the medical
expenditures of a matched group of nondiabetic individuals (see
Table 11). Per capita expenditures amount to $6,288 (4,426 to
8,150) per year where hospital inpatient visits and prescription
drugs including medical supplies account for over 75 percent of
the yearly cost attributable to T1D.
We report mean values, but the underlying population is
heterogeneous in terms of costs. There is a small subpopulation of
T1D patients who rarely experience any complications associated
with the disease. They are currently the focus of scientific studies,
though a common factor has not yet been found [53]. At the other
end of the spectrum, we use those patients who report at least one
hospital night in the past year to proxy for patients with
complications. We find that this small subpopulation spends on
average over $23,000 year, or nearly 3.5 times the mean value, on
medical care attributable to T1D, mostly attributable to the
fourfold increase in hospital inpatient expenditures.
We compare our figures to the ADA papers, noting that our
methodology differs from that of the ADA [6,2]. Removing
nursing home and hospice expenses from the ADA studies’ overall
diabetes medical cost (since MEPS only samples the non-
institutionalized population), the ADA reports $77.4 billion
(2002 dollars) and $109 billion (2007 dollars) in medical
expenditures attributed to diabetes. (Note that there are differences
in methodology, as well as data sources, between the ADA 2003
[6] and ADA 2008 [2] papers.) Our estimate of $6.9 billion in
medical expenditures falls within the 5 to 10 percent range of
overall diabetes medical expenditures (see Table 12) and is roughly
in proportion to the population factor. In comparison with Dall
et al. [13], our estimate of medical costs is lower than the $10.5
billion the authors estimate for 2007. However, of the $10.5, $4.4
billion was found to be attributed to nursing or residential facility
care. Removing this component, our estimates of medical costs
attributed to T1D are similar to those found by Dall et al.
Table 6. Mean yearly medical expenditure with at least one hospital night (2005 dollars).
Outcome T1D (1) Matched control (2) Attributed to T1D
a (1)–(2)
Hospital Inpatient 15,019 788 14,231 (10,013–18,449)
***
Ambulatory Visits 5,793 772 5,021 (2,236–7,806)
***
Prescription Drug 3,797 787 3,010 (2,257–3,763)
***
Emergency Room
b 544 98 446 (187–705)
***
Total Medical Expenditure (per capita)
b 25,858 2,720 23,137 (17,288–28,986)
***
aNinety-five percent confidence intervals in parentheses. ***, **, * indicate the 1 percent, 5 percent and 10 percent significance levels, respectively.
bOutcomes do not add up to total because total medical expenditure includes some other factors (home health care, vision, etc.) that are each small.
doi:10.1371/journal.pone.0011501.t006
Table 7. Mean yearly indirect costs for patients with T1D and
matched controls (2005 dollars).
Outcome T1D (1)
Matched
Control (2)
Attributed to T1D
(1)–(2)
a
Missed work days 10.8 5.3 5.5 (3.2–8.4)
***
Bed days 11.2 3.6 7.6 (6.4–9.5)
***
Missed school days 3.7 0.4 3.3 (2.1–4.0)
***
High school graduate (%) 47.7 48.1 20.4 (24.0–3.1)
College graduate (%) 14.4 12.7 1.7 (24.7–4.1)
Graduate education (%) 13.2 13.5 20.3 (22.7–2.1)
Individual income
b 22,958 30,122 27,164 (29,268–
26,008)
***
Household income 45,511 54,991 29,480 (211,034–
25,701)
***
a*** indicates significance at the 1 percent level, 95 percent confidence intervals
in parentheses.
bIndividual income is estimated for those over 18. Where applicable, income is
split evenly between spouses.
doi:10.1371/journal.pone.0011501.t007
Table 8. Age distribution of medical costs attributed to T1D.
Age group N Sample weighted Avg. yearly T1D medical cost
a
3–18 65 71,036 $1,981 (2918–4,880)
19–29 92 123,782 $3,573 (145–7,001)
**
30–39 127 182,145 $6,471 (2443–13,386)
*
40–49 156 213,423 $4,999 (1,661–8,337)
***
50–64 253 347,360 $7,079 (4,239–9,919)
***
65–74 70 81,385 $10,100 (3,105–17,095)
***
75+ 54 70,624 $8,709 (4,767–12,651)
***
aNinety-five percent confidence intervals in parentheses. ***, **, * indicate the 1
percent, 5 percent and 10 percent significance levels, respectively.
doi:10.1371/journal.pone.0011501.t008
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are generally comparable between our study and the ADA papers.
However, the matched control group of individuals without
diabetes in our analysis spend less on medical care than the age-sex
adjusted individuals without diabetes in the ADA paper ($3,580
(2005 dollars) in our paper compared with $4,464 (2007 dollars) in
the ADA paper). We use a matching technique to match
individuals without diabetes as closely as possible to T1D patients
based on a number of factors. Therefore, our T1D control group
may in general be healthier than the age-sex adjusted control
group used in the ADA papers (recall that we condition on being
nonobese for a portion of our sample), indicating the costs we
estimate are a lower bound of the cost attributed to T1D.
Lost Income
Total income loss estimated for the 1.1 million T1D patients in
our sample for an average year between 1999 and 2005 is $7.5
billion (4.6 billion to 10.2 billion) in 2005 dollars, as shown in
Table 11. This figure includes early mortality costs that are
estimated to be $3.0 billion for T1D patients and $2.9 billion for
those without diabetes. Thus, $120 million is attributed to early
mortality from T1D. Individuals without diabetes are estimated to
have higher incomes than patients with the disease. If those
without diabetes were to have exactly the same earnings profile as
a T1D patient, the early mortality costs attributed to the disease
would be estimated to be $1.7 billion.
T1D individuals miss 5.5 (3.2 to 8.4) more work days,
experience 7.6 (6.4 to 9.5) more bed days, and miss 3.3 (2.1 to
4.0) more school days per year than their matched counterparts.
We do not find that educational attainment is significantly affected
by T1D. These findings are consistent with other published
findings [15].
The ADA papers measure indirect costs by estimating and
valuing lost productivity through lost work days and bed days,
disability, and increased mortality [2,7]. The 2008 paper adds
presenteeism (reduced performance when at work), which is
calculated using values from the literature. See ADA, 2008 [2]
page 8 for more information. After combing the literature, the
ADA uses a productivity loss associated with diabetes (all types) of
14 days per worker per year. Our use of income loss theoretically
encompasses lost productivity due to disability, lost work days and
bed days. Presenteeism would be included insomuch as the
decreased productivity is reflected in salaries.
The per capita figure for the number of lost work and bed days
reported by the ADA is similar to our findings. The ADA finds
total indirect costs of $58 billion in 2007 dollars. Our estimate of
$7.5 billion (4.6 billion to 10.2 billion) in income loss is over 10
percent of the ADA estimation of indirect total diabetes costs.
However, mortality costs in our study are not directly comparable
to the ADA number due to important differences in methodol-
ogies. The ADA studies do not account for the possibility of early
mortality for those individuals without diabetes. Removing
mortality costs from both figures, we find that non-mortality
related indirect costs of the T1D population make up over 25
percent of the total diabetes costs (Table 12). Thus, the indirect
costs of T1D make up a disproportionately higher percentage of
the overall diabetes costs than the population factor would suggest.
Therefore, we find that it is inadequate to assume that the yearly
cost of T1D is simply the same proportion of total costs as the
number of type 1 diabetic patients compared with the total
number of patients with diabetes for indirect costs.
Dall et al. [13] estimated indirect costs by calculating the
proportion of days spent receiving medical services related to T1D
by age and gender, where office and outpatient visits accounted for
Table 9. Expected lifetime medical and indirect costs attributed to T1D by a new cohort of patients (2005 dollars).
a
Age of onset Number of new patients Medical (millions) Income loss
b (millions)
3–9 6,483 $746 (443–1,069)
*** $1,208 (667–1,749)
***
10–19 11,980 $1,489 (807–2,171)
*** $2,923 (1,604–4,242)
***
20–29 3,528 $337 (193–481)
*** $1,130 (617–1,643)
***
30–39 3,976 $395 (240–550)
*** $1,279 (841–1,717)
***
40–45 2,464 $309 (128–491)
*** $776 (402–1,150)
***
Total 28,430 $3,276 (2,098–4,454)
*** $7,316 (4,513–10,119)
***
aNinety-five percent confidence intervals in parentheses. ***, **, * indicate the 1 percent, 5 percent and 10 percent significance levels, respectively.
bIncome is compared only for those over 18 years of age, but discounted back to the age of diagnosis.
doi:10.1371/journal.pone.0011501.t009
Table 10. Expected lifetime medical and indirect costs attributed to T1D by current patients (2005 dollars).
a
Age Number of current patients Medical (millions) Income loss
b (millions)
3–9 18,543 $3,799 (2,274–5,324)
*** $5,069 (23,312–13,450)
10–19 61,642 $7,158 (4,343–9,973)
*** $11,409 (4,086–18,732)
***
20–29 114,633 $19,146 (11,620–26,672)
*** $39,085 (25,363–52,807)
***
30–39 182,145 $27,760 (19,254–36,266)
*** $69,029 (51,428–86,630)
***
40+ 712,792 $75,832 (51,871–99,793)
*** $164,624 (112,751–216,497)
***
Total 1,089,755 $133,695 (97,015–170,374)
*** $289,216 (211,727–366,705)
***
aNinety-five percent confidence intervals in parentheses. ***, **, * indicate the 1 percent, 5 percent and 10 percent significance levels, respectively.
bIncome is compared only for those over 18 years of age, but discounted back to the current age.
doi:10.1371/journal.pone.0011501.t010
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full days. The authors estimated the long-term disability costs
associated with T1D by using the proportion of hospital inpatient
days. The authors estimate that $4.3 billion in nonmedical costs
were attributed to T1D in 2007. The lower figure compared with
our findings reflect the differing methodologies between the two
studies.
Lifetime costs
It is not surprising that indirect costs make up a large portion of
total costs of T1D, given the typical early onset of the disease.
Once on a lower earnings trajectory, it may not be possible to
make up for the income difference; instead the differences may
become even more severe as time passes. The calculation of
lifetime costs of T1D, presented here for the first time, is
particularly relevant for a chronic, childhood disease such as T1D,
where costs are incurred over a long lifetime. Expected discounted
lifetime income losses of a new cohort of 30,000 T1D are
estimated to be $7.3 billion (4.5 billion to 10.1 billion). The
expected discounted lifetime medical costs patients of a new cohort
of 30,000 T1D are $3.3 billion (2.1 billion to 4.5 billion). For the
current 1.1 million T1D patients, the present value of their
expected lifetime medical and indirect costs is $133.7 billion (97.0
billion to 170.4 billion) and $289.2 (211.7 billion to 366.7 billion),
respectively.
Lifetime costs for several diseases associated with obesity are
estimated by Thompson et al. [46]. The authors calculate lifetime
medical costs attributed to obesity beginning at age 35 by BMI.
The authors focused on five diseases related to obesity:
hypertension, hypercholesterolemia, T2D, coronary heart disease,
and stroke. The discounted expected lifetime medical costs range
from $20,000 to $39,000 per person in 2005 dollars (inflated from
1996 dollars) depending upon BMI and gender. If these costs were
discounted to birth, they would be significantly smaller. This
would, however, be offset by whatever costs are incurred due to
obesity in earlier ages. We estimate the cost to a newly diagnosed
T1D patient that is age 14 to be $130,000 over his lifetime in
medical costs, which is considerably larger. For a newly diagnosed
35-year old with T1D, his expected rest-of-lifetime medical cost
attributable to the disease is $100,000. Although the methodolo-
gies in the studies differ, it is clear that lifetime costs of T1D are
substantial.
Conclusions
Until now, the economic costs specific to T1D have not been
adequately measured. Together with the recent work of Dall et al.
[13], and employing a complementary methodology, this research
is the first nationally representative cost of illness study for T1D
including lifetime costs. Our estimates show that patients with
T1D incur a disproportionately large indirect costs burden as a
result of their disease when compared with patients with T1D.
It is important to note that our analysis is likely to provide an
underestimate of the true societal costs of T1D. Due to data
limitations, we necessarily omitted costs such as nursing home
expenditures and quality-of-life effects, which may be substantial.
Dall et al. [13] find the costs of institutional care to be $4.4 billion,
a substantial portion of the total $10.5 billion the authors estimate
to be the cost of T1D. The use of income as a measure of indirect
costs is also an imperfect measure of productivity. Including
information on the type of diabetes in future waves of national
health studies would help improve future research on the
economic costs of this patient population. Comparison of lifetime
costs for T2D and other chronic diseases in future economic
studies would enhance our understanding of the economic impact
of the diseases on individuals and society. However, using
propensity score matching methods may not be as effective with
T2D patients, since lifestyle behaviors not easily captured in survey
data affect the probability of having the disease.
While continued work is required to better understand the
burden of T1D, COI studies can be used by policy makers,
researchers, advocates, doctors, patients to assess the economic
impact of the diseases on the individual and society. Used in
conjunction with more traditional biomedical research studies,
COI studies allow a more complete picture of the impacts of a
particular disease to be developed. They can add to a thorough
Table 11. Summary of estimated costs attributable to T1D (2005 dollars).
a
Cost
component Per capita costs Total yearly costs
c (in billions) Lifetime costs
d
Newly diagnosed cohort of
30,000 (in billions)
Currently diagnosed 1.1 million
patients (in billions)
Medical 6,288 (4,426–8,150) 6.9 (5.9–7.9) 3.3 (2.1–4.5) 133.7 (97.0–170.4)
Indirect
b 7,164 (6,008–9,268) 7.5 (4.6–10.2) 7.3 (4.5–10.1) 289.2 (211.7–366.7)
Total 13,452 (9,193–17,711) 14.4 (11.5–17.3) 10.6 (7.2–14.0) 422.9 (327.2–519.4)
aNinety-five percent confidence intervals are in parentheses.
bIndirect costs are comprised of lost income for those 18 and over.
cTotal yearly costs are estimated for the 1.1 million T1D patients.
dLifetime costs are the discounted present value of the expected stream of costs over the lifetime.
doi:10.1371/journal.pone.0011501.t011
Table 12. Comparison of yearly costs: T1D vs. relevant ADA
all diabetes estimates (2005 dollars).
Cost
component
T1D
(billions)
ADA – all diabetes
(billions)
a
T1D percent of
total
Medical 6.9 101.9
b 6.8%
Indirect 7.5 29.3
c 25.6%
aWe used a conservative rate of inflation of 3% per year for 2006 and 2007 from
the BLS to deflate the ADA figures.
bWe removed nursing home and hospice costs from the figure since the MEPS
does not collect information on the institutionalized population.
cThis figure was obtained by removing the $26.9 billion attributed to early
mortality from the total of $58.2 billion in indirect costs because our
methodology concerning early mortality differed significantly. If we left early
mortality costs in both the ADA and our calculations, indirect costs for T1D
would be 13.9 percent of costs for all diabetes.
doi:10.1371/journal.pone.0011501.t012
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treatment or to a better comparison among various diseases. This
study is a crucial step forward in capturing the full costs, both
yearly and over a lifetime, of T1D. We have shown that the disease
has a substantial and disproportionate economic impact, partic-
ularly in the indirect costs. Over their lifetime, a patient with T1D
incurs substantial medical and indirect costs as a result of their
disease, understanding these costs is a crucial component of
understanding the full impact of the disease.
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